These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 29283559)

  • 21. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
    J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of release of granulocyte- and granulocyte-macrophage colony-stimulating factors from phytohemagglutinin-stimulated sorted subsets of human T lymphocytes by recombinant human tumor necrosis factor-alpha. Synergism with recombinant human IFN-gamma.
    Lu L; Srour EF; Warren DJ; Walker D; Graham CD; Walker EB; Jansen J; Broxmeyer HE
    J Immunol; 1988 Jul; 141(1):201-7. PubMed ID: 2454257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients.
    Lemoli RM; Fortuna A; Fogli M; Rosti G; Gherlinzoni F; Visani G; Catani L; Gozzetti A; Tura S
    Acta Haematol; 1996; 95(3-4):164-70. PubMed ID: 8677737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host F1 mice pretreated with granulocyte colony-stimulating factor accept parental bone marrow grafts in hybrid resistance system.
    Iizuka K; Kaneko H; Yamada T; Kimura H; Kokai Y; Fujimoto J
    Blood; 1997 Feb; 89(4):1446-51. PubMed ID: 9028969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent G-CSF and chemotherapy.
    Livingston RB
    J Clin Oncol; 1998 Dec; 16(12):3917. PubMed ID: 9850040
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
    J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
    Gianni AM; Bregni M; Siena S; Magni M; Di Nicola M; Lombardi F; Tarella C; Pileri A; Bonadonna G
    J Clin Oncol; 1992 Dec; 10(12):1955-62. PubMed ID: 1280674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies.
    Cornet S; Mathé D; Chettab K; Evesque A; Matera EL; Trédan O; Dumontet C
    Mol Cancer Ther; 2016 Jun; 15(6):1238-47. PubMed ID: 26988998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
    Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
    Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of granulocyte-colony-stimulating factor and interleukin-2 on ascites formation and the survival time of nude mice bearing human ovarian cancer cells.
    Kikuchi Y; Imaizumi E; Kataoka Y; Hirata J; Kita T; Tode T; Nagata I
    Cancer Immunol Immunother; 1996 Dec; 43(5):257-61. PubMed ID: 9024501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
    Michel G; Landman-Parker J; Auclerc MF; Mathey C; Leblanc T; Legall E; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Auvrignon A; Berthou C; Bauduer F; Pautard B; Schneider P; Schaison G; Leverger G; Baruchel A
    J Clin Oncol; 2000 Apr; 18(7):1517-24. PubMed ID: 10735900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.
    Sugawara Y; Fisher SJ; Zasadny KR; Kison PV; Baker LH; Wahl RL
    J Clin Oncol; 1998 Jan; 16(1):173-80. PubMed ID: 9440740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
    Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
    Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
    Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
    Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
    J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine.
    Kolli V; Denton K; Borra D; Pulluri M; Sharma A
    Psychooncology; 2013 Jul; 22(7):1674-5. PubMed ID: 23059755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
    Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
    Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.